Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Chile | Dominican Republic | Ecuador | Germany | Greece | Hong Kong | India | Italy | Jordan | Korea | Lebanon | Malaysia | Mexico | Morocco | Pakistan | Peru | Portugal | Taiwan | Ukraine | United Arab Emirates | United Kingdom | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hayat
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Trismus|Inflammation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Ser.01 | P4 |
Unknown status |
Inflammation|Trismus |
2016-01-01 |